Skip to main content

Detail

Markus Mitterhauser
Prof PD Mag pharm Dr Markus Mitterhauser, aHPhHead of Experimental Nuclear Medicine, Director Ludwig Boltzmann Institute Applied Diagnostics

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Associate Professor

ORCID: 0000-0003-3173-5272
T +43 1 06767620420
markus.mitterhauser@meduniwien.ac.at

Further Information

Keywords

Molecular Imaging; Nuclear Medicine; Radionuclide Imaging

Research group(s)

Research interests

My main research focus is experimental Nuclear Medicine: the development and validation of molecular probes for diagnosis and therapy stratification. 

Techniques, methods & infrastructure

  • preclinical imaging lab (PIL)
  • nuclear medicine Biolabs
  • Radiopharmacy

Grants

  • new preclinical models for tracer development (2020)
    Source of Funding: FFG (Austrian Research Promotion Agency), industrienahe Dissertationen
    Principal Investigator
  • Patient involvment in Oncology (2020)
    Source of Funding: LBG (Ludwig Boltzmann Gesellschaft), PPIE
    Principal Investigator
  • Dual Isotope Imaging (2019)
    Source of Funding: FFG (Austrian Research Promotion Agency), Industrienahe Dissertationen
    Principal Investigator
  • LBI Applied Diagnostics (2015)
    Source of Funding: LBG (Ludwig Boltzmann Gesellschaft), Institute Call
    Principal Investigator
  • Der Adenosin A3 Rezeptor als neues Target für die onkologische Bildgebung mit PET (2014)
    Source of Funding: FWF (Austrian Science Fund), Einzelprojekte
    Principal Investigator
  • Simultaneous PET-MRI of the prostate for improved diagnosis and advanced radiotherapy treatment (2011)
    Source of Funding: Medical University of Vienna, CCC RCG011
    Principal Investigator
  • “[11C]DASB and ADHS (2009)
    Source of Funding: OeNB (Oesterreichische Nationalbank), Jubiläumstiftung
    Principal Investigator
  • Evaluierung von [18F]FE@SNAP und [11C]SNAP-7941 als Liganden für den MCH1 Rezeptor (2008)
    Source of Funding: FWF (Austrian Science Fund), Einzelprojekte
    Principal Investigator
  • Evaluierung von (18F)FE@SUPPY als Ligand für den A3 Rezeptor (2006)
    Source of Funding: FWF (Austrian Science Fund), einzelprojekte
    Principal Investigator
  • Preclinical Evaluation of [18F]FE@CIT (2005)
    Source of Funding: OeNB (Oesterreichische Nationalbank), Jubiläumstiftung
    Principal Investigator